Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 in hypertensive adults with type 2 diabetes mellitus
NL-OMON36022Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 12 weeks. Started Jul 2011; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON36022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36022.